CFO
CLDI icon

CVA Family Office’s Calidi Biotherapeutics CLDI Stock Holding History

CVA Family Office’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10 Hold
42
– – ﹤0.01% 1837
2025
Q4 		$49 Hold
42
– – ﹤0.01% 1283
2025
Q3 		$64 Hold
42
– – ﹤0.01% 1292
2025
Q2 		$115 Hold
42
– – ﹤0.01% 1271
2025
Q1 		$283 Hold
42
– – ﹤0.01% 1371
2024
Q4 		$575 Hold
42
– – ﹤0.01% 1194
2024
Q3 		$570 Hold
42
– – ﹤0.01% 1178
2024
Q2 		$1K Buy
+42
New +$1.34K ﹤0.01% 1074

Other funds holding CLDI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CVA Family Office's CLDI Position: Q1 2026 in Review

CVA Family Office held its Calidi Biotherapeutics (CLDI) position steady in Q1 2026 at 42 shares worth $10. The position accounts for ﹤0.01% of the portfolio, ranked #1837.

CVA Family Office first reported a position in CLDI in Q2 2024 and has held it in 8 quarters since. The position peaked at $1K in Q2 2024. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

  • CVA Family Office held 42 shares of Calidi Biotherapeutics worth $10 as of Q1 2026.
  • CVA Family Office left its Calidi Biotherapeutics share count unchanged in Q1 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1837 holding.
  • CVA Family Office first reported a position in Calidi Biotherapeutics in Q2 2024 and has held it in 8 quarters since.
  • CVA Family Office's Calidi Biotherapeutics position peaked at $1K in Q2 2024.
  • 28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.